Alvotech SA (ALVO)

7.71
+0.08(+1.05%)
  • Volume:
    31,415
  • Day's Range:
    7.71 - 8.00
  • 52 wk Range:
    5.20 - 14.04

ALVO Overview

Prev. Close
7.63
Day's Range
7.71-8
Revenue
-
Open
8
52 wk Range
5.2-14.04
EPS
-12.29
Volume
31,415
Market Cap
1.92B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
84,365
P/E Ratio
-0.604
Beta
0.132
1-Year Change
-21.49%
Shares Outstanding
248,649,505
Next Earnings Date
-
What is your sentiment on Alvotech?
or
Market is currently closed. Voting is open during market hours.

Alvotech SA Company Profile

Alvotech SA Company Profile

Employees
784

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuyNeutralSell
Technical IndicatorsSellSellBuyBuyStrong Sell
SummaryNeutralNeutralBuyNeutralStrong Sell